Evidence map›Paper›PMID 30923094›Full record

Trial reportHaematologica2019

Bortezomib-based induction followed by stem cell transplantation in light chain amyloidosis: results of the multicenter HOVON 104 trial.

Monique C Minnema, Kazem Nasserinejad, Bouke Hazenberg, Ute Hegenbart, Philip Vlummens, Paula F Ypma, Nicolaus Kröger, Ka Lung Wu, Marie Jose Kersten, M Ron Schaafsma and 9 more

Abstract readClinical Trial, Phase IIClinical Trial, Phase IIIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Haematologica, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Trial
  2. Pilot Study of Bortezomib and Dexamethasone Pre- and Post-Risk-Adapted Autologous Stem Cell Transplantation in AL Amyloidosis.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2020
    Trial
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Novel Therapies in Light Chain Amyloidosis.Kidney international reports · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Monique C MinnemaDepartment of Hematology, UMC Utrecht Cancer Center, Utrecht, the Netherlands m.c.minnema@umcutrecht.nl.
Kazem NasserinejadHOVON Data Center, Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
Bouke HazenbergDepartment of Rheumatology & Clinical Immunology, University of Groningen Medical Center, Groningen, the Netherlands.
Ute HegenbartDepartment of Hematology, Oncology and Rheumatology, Heidelberg University, Amyloidosis Center, Heidelberg, Germany.
Philip VlummensDepartment of Haematology, Ghent University, Gent, Belgium.
Paula F YpmaDepartment of Hematology, HagaZiekenhuis, Den Haag, the Netherlands.
Nicolaus KrögerDepartment of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Ka Lung WuDepartment of Hematology, ZNA Stuivenberg, Antwerp, Belgium.
Marie Jose KerstenDepartment of Hematology, Academic Medical Center, Lymphoma and Myeloma Center, Amsterdam, the Netherlands.
M Ron SchaafsmaDepartment of Hematology, Medisch Spectrum Twente, Enschede, the Netherlands.
Sandra CroockewitDepartment of Hematology, Radboud University Medical Center, Nijmegen, the Netherlands.
Esther de WaalDepartment of Hematology, University of Groningen, Medical Center, Groningen, the Netherlands.
Sonja ZweegmanDepartment of Hematology, VU University Medical Center, Amsterdam Cancer Center, Amsterdam, the Netherlands.
Lidwien TickDepartment of Internal Medicine, Maxima Medisch Centrum, Eindhoven, the Netherlands.
Annemieke BroijlDepartment of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
Harry KoeneDepartment of Hematology, St. Antonius Hospital, Nieuwegein, the Netherlands.
Gerard BosDepartment of Hematology, Maastricht University Medical Center, Maastricht, the Netherlands.
Pieter SonneveldDepartment of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
Stefan SchönlandDepartment of Hematology, Oncology and Rheumatology, Heidelberg University, Amyloidosis Center, Heidelberg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This prospective, multicenter, phase II study investigated the use of four cycles of bortezomib-dexamethasone induction treatment, followed by high-dose melphalan and autologous stem cell transplantation (SCT) in patients with newly diagnosed light chain amyloidosis. The aim of the study was to improve the hematologic complete remission (CR) rate 6 months after SCT from 30% to 50%. Fifty patients were enrolled and 72% had two or more organs involved. The overall hematologic response rate after induction treatment was 80% including 20% CR and 38% very good partial remissions (VGPR). Fifteen patients did not proceed to SCT for various reasons but mostly treatment-related toxicity and disease-related organ damage and death (2 patients). Thirty-one patients received melphalan 200 mg/m

Indexed as

Hematopoietic Stem Cell TransplantationAgedBiomarkersBortezomibCombined Modality TherapyDisease ProgressionFemaleHumansImmunoglobulin Light-chain AmyloidosisImmunophenotypingMaleMiddle AgedSeverity of Illness IndexTransplantation, AutologousTreatment OutcomeBiomarkersBortezomib

Identifiers

PMID30923094
PMCPMC6821610

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.